The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Oral decitabine-cedazuridine in combination with venetoclax in treatment-naïve HR-MDS or CMML
In this video, Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a Phase I/II clinical trial evaluating oral decitabine-cedazuridine in combination with venetoclax in patients with high-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). He highlights the encouraging results of this combination, emphasizing the need to identify specific patient subgroups who may benefit the most from this approach. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
